Stenotrophomonas maltophilia is a ubiquitous bacterium and an emerging nosocomial pathogen. This bacterium is resistant to many antibiotics, associated with a number of infections, and a significant health risk, especially for immunocompromised patients. Given that Caenorhabditis elegans shares many conserved genetic pathways and pathway components with higher organisms, the study of its interaction with bacterial pathogens has biomedical implications. S. maltophilia has been isolated in association with nematodes from grassland soils, and it is likely that C. elegans encounters this bacterium in nature. We found that a local S. maltophilia isolate, JCMS, is more virulent than the other S. maltophilia isolates (R551-3 and K279a) tested. JCMS virulence correlates with intestinal distension and bacterial accumulation and requires the bacteria to be alive. Many of the conserved innate immune pathways that serve to protect C. elegans from various pathogenic bacteria also play a role in combating S. maltophilia JCMS. However, S. maltophilia JCMS is virulent to normally pathogen-resistant DAF-2/16 insulin-like signaling pathway mutants. Furthermore, several insulin-like signaling effector genes were not significantly differentially expressed between S. maltophilia JCMS and avirulent bacteria (Escherichia coli OP50). Taken together, these findings suggest that S. maltophilia JCMS evades the pathogen resistance conferred by the loss of DAF-2/16 pathway components. In summary, we have discovered a novel host-pathogen interaction between C. elegans and S. maltophilia and established a new animal model with which to study the mode of action of this emerging nosocomial pathogen.
Stenotrophomonas maltophilia, a Gram-negative bacillus previously classified as both Pseudomonas and Xanthomonas (1), is an emerging nosocomial pathogen. From 1993 to 2004, S. maltophilia was found to be among the 11 organisms most frequently recovered from intensive care unit (ICU) patients in U.S. hospitals (2). A more recent study of patients with S. maltophilia bacteremia revealed that most cases were related to hospital admission, with some being associated with health care, such as outpatient intravenous antibiotics, treatment in a long-term-care facility, or chemotherapy (3). That study also found that intubation and ICU stay at the time of S. maltophilia bacteremia were associated with mortality (3). This is likely correlated with the propensity of S. maltophilia to adhere to plastics and form biofilms (4) and the opportunistic infection of patients with preexisting illnesses. In fact, S. maltophilia is the predominant bacterium recovered from the respiratory tract of patients with cystic fibrosis (5) and enhances the pathogenesis of Crohn's disease and ulcerative colitis (6, 7). Additionally, S. maltophilia can cause nosocomial pneumonia (8) and is associated with a number of infections, such as meningitis and endocarditis (reviewed in reference 9). Thus, S. maltophilia is a significant and medically important human pathogen. Furthermore, c...